OH-PROAMPAC
20.8.2020 17:33:05 CEST | Business Wire | Press release
ProAmpac, the flexible packaging leader, today announced the launch of their online packaging design configurator branded MAKR (pronounced Make Er). MAKR allows users to remotely create custom three-dimensional package designs in both film and paper formats which can then be prototyped at the company’s Design and Sample Lab (DASL).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200820005615/en/
“Through DASL we have been ideating, designing and prototyping samples in collaboration with customers since 2014. MAKR takes our collaboration process to another level by moving ideation and design to a virtual process. Users can interact in the app with different flexible packaging formats, sizes, shapes, and art in ways that bring their ideas to life no matter where they are located. With so many of our customers working remotely during the pandemic, providing virtual, self-serve capabilities are even more relevant,” states Sal Pellingra, vice president global application & innovation.
MAKR allows users to choose almost any flexible packaging format ProAmpac produces. The user can then custom design their own package employing features such as: package dimensions, closures, handles and even the shape of the pouch. Finally, users can add graphics and submit an order for their completed package design online. ProAmpac’s DASL team will then ensure all details are correct, finalize the order, create and ship the custom prototype directly to the requester.
“This is another great example of ProAmpac’s industry-leading innovation. We’ve consistently differentiated ourselves, not only with world-class manufacturing, but also by providing packaging design services rivaling those of design firms. MAKR expands our collaborative resources and makes it easier for customers to get products from design to market in record time,” said Pellingra. “We’ve already had great feedback from our soft launch partner customers and will build out MAKR and other virtual capabilities to continue to make it easier for customers to bring new packaging ideas to a commercial reality,” Pellingra continued.
MAKR is the newest offering in a growing number of valued-added virtual offerings for ProAmpac customers under the brand name Bridge. Earlier this year ProAmpac launched Bridge Remote Trial Management (RTM), an option that allows a ProAmpac Customer Technical Service Expert to review a customer’s product trials remotely and ensure the packaging products are running efficiently.
“At ProAmpac, serving our customers is our top priority and since the onset of COVID-19 we have experienced increasing demand in virtual support requests. This led us to fast track our digital innovation platforms. MAKR and Bridge RTM are just the beginning. We have more tools and offerings coming soon to ensure our customers are getting the virtual support and service they need,” stated Adam Grose, chief commercial officer. “We feel the launch of MAKR will make it easier for our customers to do business with ProAmpac, which is ultimately the objective behind all our digital product offerings.”
To learn more about ProAmpac’s MAKR, or other offerings available through DASL, contact Nicole Cocuzzi (Nicole.Cocuzzi @Proampac.com) or go to ProAmpac.com/DASL .
Video
Demonstration of MAKR
About ProAmpac
ProAmpac is a leading global flexible packaging company with a comprehensive product offering unparalleled in the industry. We provide creative packaging solutions, industry-leading customer service and award-winning innovation to a diverse global marketplace. We are guided in our work by four core values that are the basis for our success: Integrity, Intensity, Innovation, and Involvement. Cincinnati-based ProAmpac is owned by Pritzker Private Capital along with management and co-investors. For more information, visit ProAmpac.com.
About Pritzker Private Capital
Pritzker Private Capital partners with middle-market companies based in North America with leading positions in the manufactured products, services and healthcare sectors. The firm’s differentiated, long-duration capital base allows for efficient decision-making, broad flexibility with transaction structure and investment horizon, and alignment with all stakeholders. Pritzker Private Capital builds businesses for the long term and is an ideal partner for entrepreneur and family owned companies. For more information, visit PPCPartners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200820005615/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom